Related Experiment Video
Updated: Jul 6, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Brachytherapy for advanced prostate cancer bleeding
R Thurairaja1, R Pocock, M Crundwell
1Department of Urology, Royal Devon and Exeter Hospital, Exeter, UK. rthurairaja@doctors.org.uk
Prostate Cancer and Prostatic Diseases
|April 9, 2008
Summary
High-dose rate brachytherapy effectively treated intractable bleeding in advanced prostate cancer patients. This treatment resolved hematuria in most patients, offering a promising solution for managing this challenging symptom.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Advanced prostate cancer often presents with intractable prostatic bleeding, a difficult clinical challenge.
- Current management options for severe hematuria in this patient group can be limited.
Purpose of the Study:
- To evaluate the efficacy of intraurethral high-dose rate (HDR) brachytherapy for managing intractable prostatic bleeding in advanced prostate cancer.
- To assess the resolution rate and recurrence of hematuria following HDR brachytherapy.
Main Methods:
- A retrospective analysis of 23 advanced prostate cancer patients with intractable prostatic bleeding was conducted.
- Patients received intraurethral HDR brachytherapy using Iridium-192 with a Micro-selectron HDR machine over a 5-year period.
- Median patient age was 78 years, with a median Gleason score of 9.
Main Results:
- Hematuria resolved in 19 out of 23 patients (82.6%) following intraureral HDR brachytherapy.
- Of the patients who achieved resolution, 100% remained recurrence-free at the 6-month follow-up.
- The treatment was generally well-tolerated, with no major complications reported in the abstract.
Conclusions:
- Intraurethral high-dose rate brachytherapy is a potentially effective and palliative treatment modality for intractable hematuria in advanced prostate cancer.
- This technique offers a viable option for symptom control in patients with limited treatment alternatives.
